HEIDELBERG PHARMA AG
HEIDELBERG PHARMA AG
Share · DE000A11QVV0 · A11QVV (XFRA)
Overview Financial Indicators
4,75 EUR
5,56 % 0,25 EUR
Frankfurt (XETR) · Current prices and charts at MoneyPeak
06.06.2025 15:36

Current Prices from HEIDELBERG PHARMA AG

ExchangeTickerCurrencyLast TradePriceDaily Change
XETR: XETRA
XETRA
HPHA.DE
EUR
06.06.2025 15:36
4,75 EUR
4,50 EUR
+5,56 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 40,53 % 53,23 % 81,99 % 93,88 % 64,93 % 11,50 %

Company Profile for HEIDELBERG PHARMA AG Share

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

Company Data

Name HEIDELBERG PHARMA AG
Company Heidelberg Pharma AG
Website https://heidelberg-pharma.com
Primary Exchange XFRA Frankfurt
WKN A11QVV
ISIN DE000A11QVV0
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Prof. Andreas Pahl
Market Capitalization 122 Mio
Country Germany
Currency EUR
Employees 0,1 T
Address Gregor-Mendel-Strasse 22, 68526 Ladenburg
IPO Date 2006-11-13

Ticker Symbols

Name Symbol
Frankfurt HPHA.F
XETRA HPHA.DE

More Shares

Investors who HEIDELBERG PHARMA AG hold also have the following shares in their portfolio:
ALIBABA GR. SP.ADR 8
ALIBABA GR. SP.ADR 8 Share
ALPHABET INC - CLASS A
ALPHABET INC - CLASS A Share
APPLE INC
APPLE INC Share
BIONTECH SE ADR
BIONTECH SE ADR Share
LLOYDS BANK PLC CALL DUAL RNGE ACCR NTS 12/02/25
LLOYDS BANK PLC CALL DUAL RNGE ACCR NTS 12/02/25 Bond
MERCEDES BENZ GROUP AG
MERCEDES BENZ GROUP AG Share
MICROSOFT CORP
MICROSOFT CORP Share
NVIDIA CORP
NVIDIA CORP Share
PROCTER GAMBLE CORP
PROCTER GAMBLE CORP Share
SAP SE
SAP SE Share
SERNVCORP
SERNVCORP Share
SPDR S+P US EN.SEL.S.UETF
SPDR S+P US EN.SEL.S.UETF ETF
VALNVSE        EO -,15
VALNVSE EO -,15 Share
XIAOMI CORP CL.B
XIAOMI CORP CL.B Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025